Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135614 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT02135614 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 189 participants.
The verdict
NCT02135614, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effects of presatovir on respiratory syncytial virus (RSV) viral load in RSV-positive adults who have been hospitalized with acute respiratory infectious symptoms. Participants will receive 1 dose of presatovir on Day 1 and followed for 27 days postdose. Nasal swabs will be collected at each study visit (excluding Day 28) and assayed for change in viral load as the primary endpoint.
Interventions
- DRUG Presatovir
- DRUG Presatovir placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2014-06-09 |
| Est. Completion | 2017-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02135614
The ClinicalTrials.gov registry entry for NCT02135614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Presatovir is the first listed.
NCT02135614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02135614 about?
NCT02135614 is a clinical study titled "Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection". The primary objective of this study is to evaluate the effects of presatovir on respiratory syncytial virus (RSV) viral load in RSV-positive adults who have been hospitalized with acute respiratory infectious symptoms. Participants will receive 1 dose of presatovir on Day 1 and followed for 27 days...
What is the current status of trial NCT02135614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2014-06-09. Estimated completion is 2017-04-12.
What interventions are being tested in trial NCT02135614?
The interventions under investigation include: Presatovir (DRUG), Presatovir placebo (DRUG).
Who is sponsoring clinical trial NCT02135614?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.